Agresta L, et al. - Efficacy and safety of pazopanib therapy for desmoid tumors/aggressive fibromatosis (DT/AF) were investigated in adolescent and young adult (AYA) patients. With exception of 1 case of edema, response to dose reduction was noted in all other toxicities without sacrificing objective treatment response. For DT/AF, pazopanib was found to be a well-tolerated therapy in the AYA population.